본문 바로가기

Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA19(3) · pp.149 · 2019
피인용
Web of Science 9Scopus 9
FWCI (Scopus)
0.19
JCR IF
JCR 2018 2.274
ISSN
2152-2650

저자

  1. 박성우제1저자Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
  2. Jo, Jae-CheolDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
  3. Do, Young RokDivision of Hematology-Oncology, Keimyung University, School of Medicine, Keimyung University Hospital, Daegu, South Korea
  4. Yang, Deok-HwanDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea
  5. Lim, Sung-NamDepartment of internal medicine, Inje university college of medicine, Haeundae Paik hospital, Busan, South Korea
  6. Lee, Won-SikDepartment of Internal Medicine, Division of Hemato-Oncology, Inje University Busan Paik Hospital, Busan, South Korea
  7. Kim, Won SeogDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  8. Lee, Ho SupDivision of Hematology-Oncology, Kosin University Gospel Hospital, Busan, South Korea
  9. Hong, Dae-SikDepartment of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Bucheon, South Korea
  10. Kim, Hyo JungDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea
  11. 신호진교신저자Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea

초록

We assessed 53 patients aged >= 65 years in South Korea to evaluate the efficacy and toxicity of reduced-dose (RD) rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy for elderly patients with diffuse large B-cell lymphoma. RD-R-CHOP chemotherapy showed comparable survival benefits compared to those who received previous RD-R-CHOP-like chemotherapy. Introduction: Elderly patients are more prone to encounter some adverse factors when they receive chemotherapy compared to younger patients. Addition of rituximab to a reduced dose (RD) of cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy might improve patient outcomes with an improved toxicity profile when provided to elderly patients with diffuse large B-cell lymphoma. Patients and Methods: A total of 53 patients aged >= 65 years with diffuse large B-cell lymphoma diagnosed between August 2012 and December 2014 were enrolled onto this study. RD-R-CHOP regimen consisted of rituximab at 375 mg/m(2), cyclophosphamide at 600 mg/m(2), doxorubicin at 30 mg/m(2), and vincristine at 1 mg on day 1 of each cycle and 40 mg of prednisone on days 1 to 5. Patients received granulocyte colony-stimulating factor if they experienced grade 3/4 neutropenia or febrile neutropenia during any cycle. Results: The median follow-up duration was 18 months (range, 1-44 months). Complete response and overall response rates were 64.1% and 81.1%, respectively. Three-year event-free and overall survival rates were 45.7% +/- 8.4% and 62.7% +/- 8.1%, respectively. Grade 3/4 neutropenia occurred in 20 patients (37.7%), while febrile neutropenia occurred in 7 patients (20.7%). Conclusion: Outcomes of RD-R-CHOP chemotherapy were comparable to those of standard-dose R-CHOP or previous dose-adjusted R-CHOP chemotherapy. In the future, strategies such as tailored therapy based on geriatric assessment results are needed to determine the chemotherapeutic dosage.

키워드

Chemotherapeutic dosageLymphoproliferative disordersOlder patientsPrognostic factorsToxicityNON-HODGKINS-LYMPHOMACOLONY-STIMULATING FACTORPLUS RITUXIMABFEBRILE NEUTROPENIARESPONSE CRITERIAIMPACTRISKCYCLOPHOSPHAMIDEVINCRISTINEDOXORUBICIN

식별자

Scopus EID
2-s2.0-85058694440
WoS UID
000459339200009